Nkarta, Inc. (NKTX)
| Market Cap | 80.31M -37.5% |
| Revenue (ttm) | n/a |
| Net Income | -128.94M |
| EPS | -1.73 |
| Shares Out | 71.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 663,712 |
| Open | 1.170 |
| Previous Close | 1.150 |
| Day's Range | 1.120 - 1.210 |
| 52-Week Range | 1.105 - 3.720 |
| Beta | 1.26 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+837.5%) |
| Earnings Date | Nov 5, 2026 |
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 837.50% from the latest price.
News
Nkarta announces integrated safety results from 40 patients treated with NKX019
Nkarta (NKTX) announced integrated safety results from 40 patients treated with NKX019, an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy candidate in its ongoing Ntrust clinical trial p...
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), ...
Nkarta Transcript: Study update
NKX019 was generally well tolerated in 40 patients, with no observed CRS, ICANS, IEC-HS or GVHD. At 4B cells per dose, 83% of evaluable myositis patients responded and 6 of 7 systemic sclerosis patients reached rCRISS-25 or higher by day 90; pivotal-dose selection is planned for H1 2027.
Nkarta Press release: Study update
Nkarta issued a press release on November 9, 2026, disclosing material business information to investors.
Nkarta Slides: Study update
Nkarta has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Nkarta announces initial clinical data from Ntrust clinical trial program
Nkarta (NKTX) announced initial clinical data from its Ntrust clinical trial program evaluating NKX019, its allogeneic, off-the-shelf CAR NK cell therapy candidate. Initial clinical data from the Ntru...
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in th...
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat aut...
Nkarta reports Q3 EPS (45c), consensus (38c)
Nkarta (NKTX) had cash, cash equivalents, restricted cash, and investments in marketable securities of $216M as of September 30. The company said, “NKX019 is advancing in our two lead indications,…
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat aut...
Nkarta Quarterly report: Q3 2026
Nkarta has published its Q3 2026 quarterly earnings report on November 5, 2026.
Nkarta Earnings release: Q3 2026
Nkarta released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Nkarta assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Nkarta (NKTX) with a Buy rating and $12 price target The company has a “differentiated CAR-NK program with a timely opportunity to establish its value,”…
Nkarta Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
A novel off-the-shelf CD19 CAR NK cell therapy for autoimmune diseases is advancing through streamlined outpatient trials, with strong safety and promising efficacy data to be presented at ACR 2026. Regulatory support enables rapid enrollment and plans for pivotal trials by 2027.
Nkarta Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted progress in off-the-shelf CAR-NK cell therapy for autoimmune diseases, with phase I-II trials ongoing and first data expected at ACR. Scleroderma and myositis are prioritized for phase III, with a focus on efficacy, safety, and patient-reported outcomes.
Nkarta to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea...
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta price target lowered to $10 from $11 at Stifel
Stifel analyst Stephen Willey lowered the firm’s price target on Nkarta (NKTX) to $10 from $11 and keeps a Buy rating on the shares after having updated the firm’s model…
Nkarta price target lowered to $14 from $16 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Nkarta (NKTX) to $14 from $16 and keeps a Buy rating on the shares. The firm cites the company’s…
Nkarta reports Q2 EPS (54c), consensus (36c)
“Expanding access to NKX019 in the communities where autoimmune patients already receive care is central to how we’re advancing this program,” said Paul J. Hastings, Chief Executive Officer of Nkarta…
Nkarta Earnings release: Q2 2026
Nkarta released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Nkarta Quarterly report: Q2 2026
Nkarta has published its Q2 2026 quarterly earnings report on August 10, 2026.
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nr...
Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
A novel CD19-directed CAR-NK cell therapy is advancing through multiple autoimmune disease trials, with a focus on safety, outpatient accessibility, and durable remissions. Key data updates in 2026 will inform future development, with redosing flexibility and regulatory engagement planned.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.